E
89bio
ETNB
9.46000
USD
0.27
(2.94%)
مغلق
حجم التداول
64,855
الربح لكل سهم
0
العائد الربحي
0
P/E
-5
حجم السوق
969,076,418
العنوان: 89bio
القطاع: Healthcare
الصناعة: Biotechnology
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).